They found that PALB2 carriers were not more common in prostate cancer patients overall, but were common in those diagnosed with aggressive prostate cancers of high grade (Gleason score 8–10) than noncarriers (64.3% vs. 18.1%, p < 0.0001). This evidence concerns the gene PALB2 and Familial prostate cancer.